亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT).

医学 卡培他滨 胆囊癌 瓦特壶腹 内科学 临床终点 胆管 胆囊 胃肠病学 危险系数 不利影响 胆道 外科 癌症 辅助治疗 胆管癌 癌 临床试验 置信区间 结直肠癌
作者
Masafumi Ikeda,Kohei Nakachi,Masaru Konishi,Shogo Nomura,Hiroshi Katayama,Tomoko Kataoka,Katsuhiko Uesaka,Hiroaki Yanagimoto,Soichiro Morinaga,Hiroshi Wada,Kazuaki Shimada,Yu Takahashi,Toshio Nakagohri,Kunihito Gotoh,Ken Kamata,Yasuhiro Shimizu,Makoto Ueno,Hiroshi Ishii,Takuji Okusaka,Junji Furuse
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 382-382 被引量:34
标识
DOI:10.1200/jco.2022.40.4_suppl.382
摘要

382 Background: Capecitabine is usually used for patients with curatively resected biliary tract cancer (BTC) in EU and US, but no clear survival benefit has been shown in phase III trials. S-1, an oral fluoropyrimidine derivative, has shown promising efficacy, with a mild toxicity profile, in patients with advanced BTC. The aim of this trial was to confirm whether adjuvant S-1 therapy might improve the overall survival (OS) in patients with curatively resected BTC. Methods: This open-label, multicenter, randomized phase III trial was conducted in 38 Japanese hospitals. Eligible patients were aged 20 to 80 years old, had undergone R0/R1 resection for histologically confirmed adeno(squamous) carcinoma of the extrahepatic bile duct, gallbladder or ampulla of Vater (T2-4, N0, M0 or T1-4, N1, M0) or the intrahepatic bile duct (T1-4, N0-1, M0) (7th UICC classification), and had an ECOG performance status (PS) of 0 or 1.The calculated sample size was 440 to detect hazard ratio for OS of 0.74 with one-sided alpha of 5% and a power of 80%. Patients in surgery-alone arm received no further anti-cancer treatment, while those in adjuvant S-1 arm received 4 cycles of oral S-1 chemotherapy at the dose of 40 mg/m 2 twice daily for 4 weeks, followed by 2 weeks of rest. Primary endpoint was OS, and secondary endpoints were relapse-free survival (RFS), incidence of adverse events, and proportion of treatment completion. Results: A total of 440 patients (surgery-alone, n = 222; adjuvant S-1, n = 218) were enrolled from September 2013 to June 2018. The data cutoff date was June 23, 2021, and the median follow-up duration was 45.4 months. Of all randomized patients, OS was significantly longer with adjuvant S-1 than surgery-alone (hazard ratio [HR] 0.694, 95%CI, 0.514-0.935; one-sided p = 0.008; the 3-year OS, 67.6% [surgery-alone; 95%CI, 61.0-73.3%] and 77.1% [adjuvant S-1; 95%CI, 70.9-82.1%]). Adjuvant S-1 was also better for RFS (HR 0.797 [95%CI, 0.613-1.035], 3-year RFS, 50.9% [surgery-alone; 95%CI, 44.1-57.2%] and 62.4% [adjuvant S-1; 95%CI, 55.6-68.4%]). All preplanned subgroup analyses (PS, age, cancer type, cancer stage, R factor, and serum CA19-9) revealed favorable OS and RFS for adjuvant S-1 arm. The main grade 3-4 adverse events in adjuvant S-1 arm were biliary tract infection (7.2%), diarrhea (2.9%), appetite loss (2.9%), fatigue (2.9%), and the treatment was well-tolerated. Conclusions: Adjuvant S-1 therapy led to significantly longer survival than surgery alone and becomes the standard of care for resected BTC. Clinical trial information: UMIN000011688.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎的应助被leo采纳,获得10
9秒前
优雅的大白菜完成签到 ,获得积分10
13秒前
李李李完成签到 ,获得积分10
16秒前
CipherSage的应助被VuuVuu采纳,获得10
17秒前
传奇3的应助被VuuVuu采纳,获得10
17秒前
汉堡包的应助被刘研采纳,获得10
20秒前
Peiqi的应助被大气吐司采纳,获得10
26秒前
28秒前
28秒前
29秒前
刘研发布了新的文献求助10
33秒前
欢呼亦竹发布了新的文献求助10
34秒前
leo发布了新的文献求助10
34秒前
34秒前
40秒前
希望天下0贩的0的应助被leo采纳,获得30
40秒前
初景的应助被Kyrie采纳,获得20
44秒前
忧郁思远完成签到,获得积分10
46秒前
49秒前
orixero的应助被科研通管家采纳,获得10
49秒前
49秒前
柳贯一发布了新的文献求助10
56秒前
59秒前
星野的应助被白华苍松采纳,获得10
1分钟前
NA01UM10完成签到,获得积分10
1分钟前
回家放羊完成签到 ,获得积分10
1分钟前
1分钟前
leo发布了新的文献求助30
1分钟前
1分钟前
fheu发布了新的文献求助10
1分钟前
1分钟前
感性的远航完成签到,获得积分10
1分钟前
yc发布了新的文献求助10
1分钟前
科研通AI65的应助被yc采纳,获得10
1分钟前
平城落叶完成签到,获得积分10
1分钟前
顾矜的应助被leo采纳,获得10
1分钟前
Yanyu完成签到,获得积分10
1分钟前
suge完成签到,获得积分10
1分钟前
2分钟前
清脆世界完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190085
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852078
捐赠科研通 7788267
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559977
邀请新用户注册赠送积分活动 2482845